<DOC>
	<DOCNO>NCT00790946</DOCNO>
	<brief_summary>The purpose study consider follow point patient hypertension complicate metabolic syndrome Valsartan basis treatment exist , standard treatment . - Blood pressure control - Changing adiponectin plasminogen activator inhibitor-1 - Influence metabolize cardiac function , etc .</brief_summary>
	<brief_title>Kagoshima Collaborate Trial Metabolic Syndrome ( KACT Study )</brief_title>
	<detailed_description>The primary endpoint : - blood pressure control - Adiponectin plasma type1 plasminogen active inhibitor The secondary endpoint - HOMA-IR - HbA1c - TNF-α - IL-6 - Plasma B-type natriuretic peptide - LVMI - E/A ratio - Tei-index - Apo-J</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<criteria>Out patient hypertension male female Systolic blood pressure ( SBP ) ≧140mmHg and/or diastolic blood pressure ( DBP ) ≧90 mmHg Waist Surrounding diameter male≧85cm female≧90cm Patient treat either high triglyceride , low HDL , diabetes mellitus Patient untreatment high triglyceride blood syndrome low HDL blood syndrome , diabetes mellitus triglceride≧150mg/dl and/or HDL cholesterol &lt; 40 mg/dl fast blood glucose ≧110 mg/dl Untreated patient hypertension , patient treat antihypertensive agent except ACEI ARB Patient use ACEI ARB Serum creatinine ≧ 3 mg/dl Liver impairment History allergy valsartan Pregnant woman Judgment physician participation unwise basis patient characteristic drug safety</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>valsartan</keyword>
	<keyword>Metabolic syndrome</keyword>
</DOC>